Last reviewed · How we verify

TRUVADA™ or EPZICOM™/KIVEXA™

Merck Sharp & Dohme LLC · Phase 3 active Small molecule

TRUVADA™ or EPZICOM™/KIVEXA™ is a NRTI Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Treatment of HIV-1 infection in adults and pediatric patients 2 years of age and older, Prevention of HIV-1 infection in adults at high risk.

TRUVADA and EPZICOM/KIVEXA are antiretroviral medications used to treat HIV-1 infection by inhibiting viral replication.

TRUVADA and EPZICOM/KIVEXA are antiretroviral medications used to treat HIV-1 infection by inhibiting viral replication. Used for Treatment of HIV-1 infection in adults and pediatric patients 2 years of age and older, Prevention of HIV-1 infection in adults at high risk.

At a glance

Generic nameTRUVADA™ or EPZICOM™/KIVEXA™
SponsorMerck Sharp & Dohme LLC
Drug classNRTI
TargetReverse transcriptase
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

TRUVADA contains emtricitabine and tenofovir disoproxil fumarate, which are nucleoside reverse transcriptase inhibitors (NRTIs). EPZICOM/KIVEXA contains abacavir and lamivudine, which are also NRTIs. These medications work by blocking the reverse transcriptase enzyme, preventing the virus from replicating.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about TRUVADA™ or EPZICOM™/KIVEXA™

What is TRUVADA™ or EPZICOM™/KIVEXA™?

TRUVADA™ or EPZICOM™/KIVEXA™ is a NRTI drug developed by Merck Sharp & Dohme LLC, indicated for Treatment of HIV-1 infection in adults and pediatric patients 2 years of age and older, Prevention of HIV-1 infection in adults at high risk.

How does TRUVADA™ or EPZICOM™/KIVEXA™ work?

TRUVADA and EPZICOM/KIVEXA are antiretroviral medications used to treat HIV-1 infection by inhibiting viral replication.

What is TRUVADA™ or EPZICOM™/KIVEXA™ used for?

TRUVADA™ or EPZICOM™/KIVEXA™ is indicated for Treatment of HIV-1 infection in adults and pediatric patients 2 years of age and older, Prevention of HIV-1 infection in adults at high risk.

Who makes TRUVADA™ or EPZICOM™/KIVEXA™?

TRUVADA™ or EPZICOM™/KIVEXA™ is developed by Merck Sharp & Dohme LLC (see full Merck Sharp & Dohme LLC pipeline at /company/merck).

What drug class is TRUVADA™ or EPZICOM™/KIVEXA™ in?

TRUVADA™ or EPZICOM™/KIVEXA™ belongs to the NRTI class. See all NRTI drugs at /class/nrti.

What development phase is TRUVADA™ or EPZICOM™/KIVEXA™ in?

TRUVADA™ or EPZICOM™/KIVEXA™ is in Phase 3.

What are the side effects of TRUVADA™ or EPZICOM™/KIVEXA™?

Common side effects of TRUVADA™ or EPZICOM™/KIVEXA™ include Nausea, Diarrhea, Fatigue, Headache, Dizziness, Abdominal pain.

What does TRUVADA™ or EPZICOM™/KIVEXA™ target?

TRUVADA™ or EPZICOM™/KIVEXA™ targets Reverse transcriptase and is a NRTI.

Related